UTHR

United Therapeutics Corporation

228.17 USD
-0.57 (-0.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

United Therapeutics Corporation stock is up 7.24% since 30 days ago. The next earnings date is May 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48% of the previous 24 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 6 PUTs, 4 CALLs. 75% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
23 Jan 19:12 16 Aug, 2024 200.00 PUT 148 89
25 Jan 19:32 17 May, 2024 300.00 PUT 160 4
07 Feb 19:26 16 Aug, 2024 165.00 PUT 155 5
08 Feb 15:46 15 Mar, 2024 220.00 CALL 72 213
13 Feb 18:47 17 May, 2024 230.00 CALL 53 61
15 Feb 20:55 16 Aug, 2024 240.00 PUT 30 0
16 Feb 18:16 17 May, 2024 220.00 CALL 33 232
16 Feb 19:56 15 Mar, 2024 230.00 CALL 100 116
04 Mar 18:00 16 Aug, 2024 240.00 PUT 14 30
04 Mar 19:14 16 Aug, 2024 240.00 PUT 35 30

About United Therapeutics Corporation

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)

  • Wedbush
    Thu Feb 22, 08:19
    buy
    confirm
  • HC Wainwright & Co.
    Thu Feb 22, 06:46
    buy
    confirm
  • Goldman Sachs
    Mon Feb 12, 05:14
    hold
    upgrade
  • Leerink Partners
    Mon Feb 5, 07:13
    buy
    initial